Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia

The standard treatment for elderly patients with acute myeloid leukemia (AML) is venetoclax (Ven), a BCL-2–selective inhibitor, combined with hypomethylating agents (HMA) such as azacitidine or decitabine. This regimen results in low toxicity, high response rates, and potentially durable remission;...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamachi, Kazuharu, Ureshino, Hiroshi, Watanabe, Tatsuro, Yoshida-Sakai, Nao, Fukuda-Kurahashi, Yuki, Kawasoe, Kazunori, Hoshiko, Toshimi, Yamamoto, Yuta, Kurahashi, Yuki, Kimura, Shinya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973401/
https://www.ncbi.nlm.nih.gov/pubmed/36860654
http://dx.doi.org/10.1158/2767-9764.CRC-22-0259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973401/
https://www.ncbi.nlm.nih.gov/pubmed/36860654
http://dx.doi.org/10.1158/2767-9764.CRC-22-0259

Ejemplares similares